Immunotherapeutics for nosocomial infections.
Nosocomial or hospital-acquired infections are associated with prolonged hospitalisation and increased healthcare costs and resource utilisation. Continued advances in sophisticated medical procedures, an increase in the number of immunocompromised patients and a steady rise in the prevalence of antibiotic-resistant organisms has renewed interest in the development of novel therapies that can treat nosocomial infections. This review focuses on novel immunological approaches to address this significant unmet medical need.
Patti
Joseph M
JM
Inhibitex Inc., 1165 Sanctuary Parkway, Suite 400, Alpharetta, GA 30004, USA. jpatti@inhibitex.com
D018528:ATP-Binding Cassette Transporters / Q000627:therapeutic use; D018829:Adhesins, Bacterial / Q000276:immunology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003428:Cross Infection / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy / Q000379:methods* / Q000706:statistics & numerical data; D016233:Immunotherapy, Active; D008070:Lipopolysaccharides / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013682:Teichoic Acids / Q000276:immunology
D018528:ATP-Binding Cassette Transporters; D018829:Adhesins, Bacterial; D008070:Lipopolysaccharides; D011135:Polysaccharides, Bacterial; D013682:Teichoic Acids; C009900:lipoteichoic acid